Clinical and Translational Epidemiology

NCI and others at NIH invite studies of cannabis and cannabinoid use among cancer patients due to the rapidly increasing availability of cannabis and cannabinoid products, their delivery methods, and the dearth of information available on their harms and benefits during treatment.

EGRP is interested in supporting research that improves understanding of how biomarkers can be used in early detection/screening of cancer.

NCI and the National Institute of Aging (NIA) are fostering research that characterizes aging phenotypes and identifies treatment-associated changes in aging trajectories in cancer survivors, with the ultimate goal of developing interventions to optimize health outcomes.

NCI and others at NIH are supporting efforts to improve cancer outcomes by mitigating unnecessary emergency department (ED) use and developing risk-based stratification and management guidelines for cancer care in the ED.

NCI and the National Heart, Lung, and Blood Institute (NHLBI) are supporting research to understand, prevent, and manage cancer treatment-related cardiovascular dysfunction while optimizing cancer outcomes.

Staff in EGRP partner with others at NCI and NIH to foster research to better understand the causes of health disparities and develop interventions to reduce differences in the incidence, prevalence, mortality, and burden of cancer and related adverse health conditions that exist among specific population groups in the United States.

NCI, under the auspices of the Cancer Moonshot initiative, is supporting research to improve the current state of genetic counseling and testing, prevention, and early detection for those at high-risk for cancer.

CTEB and others at NCI are interested in supporting research that identifies patients at the highest risk for both short- and long-term adverse events and to identify treatment regimens that may reduce such risks and improve quality of life.